AOP-208

Last updated

AOP-208
Clinical data
Other namesAOP208; LB-208; LB208
Routes of
administration 		Oral [1] [2]
Drug class Serotonin 5-HT1B receptor antagonist

AOP-208, also known as LB-208, is a selective serotonin 5-HT1B receptor antagonist which is under development for the treatment of lymphoma, solid tumors, acute myeloid leukemia, and myelodysplastic syndromes. [1] [3] [2] It is taken orally. [1] [2] The drug is being developed by AOP Orphan Pharmaceuticals AG and Leukos Biotech. [1] [3] As of October 2024, it is in phase 1 clinical trials for lymphoma and solid tumors and is in the preclinical research stage of development for acute myeloid leukemia and myelodysplastic syndromes. [1] [3] The chemical structure of AOP-208 does not yet appear to have been disclosed. [1]

References

  1. 1 2 3 4 5 6 "AOP 208". AdisInsight. 8 October 2024. Retrieved 24 January 2026.
  2. 1 2 3 Rojas Laimito K, Molina Lores G, Nuciforo P, Smiljkovic D, Unger M, Krejcy K, et al. (2025). "1024eTiP LB-208/AOP208 a first-in-class HTR1B antagonist: First-in-human, dose finding phase I study for the evaluation of safety, pharmacokinetics, pharmacodynamics, and anti-tumor activity in adult patients with relapsed or refractory solid tumors or lymphoma". Annals of Oncology. 36: S625. doi:10.1016/j.annonc.2025.08.1593 . Retrieved 24 January 2026.
  3. 1 2 3 "Delving into the Latest Updates on AOP-208 with Synapse". Synapse. 19 July 2025. Retrieved 24 January 2026.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.